We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Allogeneic marrow transplantation for refractory Hodgkin's disease.
- Authors
Phillips, G L; Reece, D E; Barnett, M J; Connors, J M; Fay, J W; Herzig, G P; Herzig, R H; Klingemann, H G; Shepherd, J D; Wolff, S N
- Abstract
Eight patients with refractory Hodgkin's disease received intensive combination chemotherapy conditioning with cyclophosphamide, carmustine (BCNU), and etoposide (VP 16-213), and allogeneic marrow transplants. All patients achieved complete responses. Three patients relapsed; two died of Hodgkin's disease and one of chronic graft-v-host disease (GVHD) and infection. In all, four patients died due to transplant-related toxicity. One patient developed a fatal B-cell lymphoproliferative disorder soon after transplantation, and died without evidence of Hodgkin's disease. One patient is alive and free of progression 29 months after transplantation. These data indicate that allogeneic marrow transplantation may be considered as therapy for selected patients with advanced Hodgkin's disease and, despite substantial toxicity, will occasionally result in long-term responses. Better patient selection would likely improve results.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Vol 7, Issue 8, p1039
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.1989.7.8.1039